ARCHIVES

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

This article is from The Cancer Letter archive.

Vol. 28 No. 1 | January 28, 2005

Download PDF Visit The Full Archive

Related Articles

NCAB working Group Is Not Subject To Open Meetings Law, NCI Official Says

December 9, 1994

Cancer Meetings Listed for Next Three Months

January 19, 1996

NCCS Names 7 To Board; FDA Approves Warning Labels for Hormone Therapy

January 17, 2003

House Subcommittee voted $1.011 Billion For NCU 1981 Fiscal Year Budget In Closed Door Meeting

August 8, 1980

CAP, ASCCP Recommendations Standardize Lesion Terminology

July 27, 2012

Final Money Bill Clear On Permitting New Construction Funding

December 12, 1975